BioSpace News Archive

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months GSK to make equity investment of $250 million in Vir LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.

Janssen Pharmaceutical has published comprehensive data from studies evaluating the safety of Tremfya

Hope Biosciences, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COV

Endologix, Inc. today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately $28.5 million.

Avita Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced preliminary estimates of its top line results for the three months ended 31 March 2020, together with an operating update relating to the COVID-19 pandemic.

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company’s website: www.medivir.com . The development in 2019 shows that the reorganization and refocus that was initiated at the end of 2018 was right for Medivir. Today we are an agile and efficient development company wit

Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company’s operational and clinical activities.

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it was the first to receive approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter (“OTC”) diclofenac sodium topical gel 1%. On February 14, 2020 , the FDA approved Voltaren® Arthritis Pain (diclofenac sodium topical

- Up to 40 Healthy Volunteers To Participate at Two Trial Locations - Preclinical Animal Studies Show Promising Immune Responses - Rapid Advancement Possible Through a Global Coalition of Collaborators, Partners, and Funders